Inve India ▾

Shilpa Medicare share price & results

Shilpa Medicare Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Vertically integrated pharma group making APIs, complex formulations, biosimilars and CDMO services.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue189 ₹ crore+105.4% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin30.0 %+12.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit65.0 ₹ crore+209.5% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity11.50 %+4.7 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin-1.89 %+6.9 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)27.98 %+8.0 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

6 of 12 judged targets kept · 23 open · verdicts reflect calls analysed to Q1 FY27.

Shilpa Medicare Limited management guidance track record on Inve: 35 targets tracked across analysed earnings calls (6 achieved, 6 missed, 23 open).

TargetOriginal wordingSaidLatest callVerdict
Nor-UDCA Formulation Launchlaunch is planned in first half of FY '26
Call transcript, Q4 FY25 · 26 May 2025		Q4 FY25Q1 FY27:Management confirmed the product is 'doing good' but was evasive on providing specific sales data. Phase IV clinical study is ongoing.
Call transcript, Q1 FY27 · 5 Aug 2026		Achieved*
Unicycive Dedicated Block Commissioningexpected to be completed in first half of FY '26
Call transcript, Q4 FY25 · 26 May 2025		Q4 FY25Q1 FY27:No mention of the block's commissioning.
Call transcript, Q1 FY27 · 5 Aug 2026		Ghosted
Unicycive Block Exhibit Batchesexhibit batches will be taken in Q1 FY '27
Call transcript, Q3 FY26 · 6 Feb 2026		Q3 FY26Q1 FY27:No specific mention of exhibit batches, but the overall program is now expected to be commercialized in FY28, implying a delay.
Call transcript, Q1 FY27 · 5 Aug 2026		Delayed

Source: Inve Guidance Tracker for Shilpa Medicare Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

6 of Shilpa Medicare Limited's 35 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 32 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹904.7 +0.43% · +₹3.9

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +148.8% 1Y

₹0.4k₹0.6k₹0.8k₹1.0kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 17 Nov 2025Q3 FY26 — 6 Feb 2026Q4 FY26 — 26 May 2026Q1 FY27 — 5 Aug 2026

1Y: ₹363.6 on 24 Oct 2025 → ₹904.7. High ₹1,073.7 (6 Oct 2026), low ₹267 (23 Jan 2026).

Previous close
₹900.8
Market cap
₹17.6k Cr
52-week range
₹267 – ₹1,073.7
One year
+144.25%
Price to earnings (TTM to Jun 2026)
61.82×
Return on equity (TTM to Jun 2026)
11.50%

Overview

Symbol
NSE:SHILPAMED
Exchange
NSE
Currency
INR

What Shilpa Medicare Limited does

Based on the company's own presentations, annual report and earnings calls.

Shilpa Medicare Limited, founded in 1987 and headquartered in Raichur, Karnataka, is a vertically integrated pharmaceutical company operating across Active Pharmaceutical Ingredients (API), Finished Dosage Formulations, Biologics/Biosimilars and Contract Development & Manufacturing Organisation (CDMO) services. It develops and manufactures complex oncology and non-oncology APIs, peptides and bio-polymers that feed its own formulations business (tablets, capsules, injectables, oral dissolving films and transdermal patches), while its Biologics arm develops monoclonal antibodies, antibody-drug conjugates (ADCs) and novel biologic entities for global pharma partners. The company also runs emerging platforms in novel drug delivery systems (NDDS), ADCs and recombinant human albumin, and earns CDMO income through development, manufacturing and licensing partnerships with global biotech and pharma companies.

Segments

  • API
  • Formulations
  • Biologics/Biosimilars
  • CDMO
Regulatory-approved manufacturing and R&D facilities
10+ (incl. analytical lab)
Worldwide market presence
50+ countries
R&D personnel
400+
Cumulative regulatory filings worldwide
500+
Operating track record
35+ years (founded 1987)
Key manufacturing sites
Raichur (API, headquarters), Jadcherla (potent oncology formulations, OEL-4 containment), Dabaspet (transdermal patches and oral dissolving films), Dharwad (integrated biologics — microbial and mammalian expression systems)
Founded 1987Headquarters Raichur, Karnataka, India Company website

How the price took the results

close before → close after

Q1 FY27
+12.0%
5 Aug
Q4 FY26
−1.4%
26 May
Q3 FY26
0.0%
6 Feb
Q2 FY26
−1.3%
17 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Shilpa Medicare Limited

Free account: one company. Everything above stays public.

Write why you follow Shilpa Medicare Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Shilpa Medicare Limited

Guides on how to read this kind of business and the numbers that matter.